DEFA14A: Schwazze Inc. to Hold Annual Meeting, Seeks Stockholder Approval on Key Proposals

Schwazze Inc. (d/b/a Schwazze) will hold its annual meeting on June 20, 2024, seeking stockholder approval on director elections, auditor ratification, and amendments to its equity incentive plan and articles of incorporation.

Summary

• Medicine Man Technologies, Inc. d/b/a Schwazze will hold its 2024 Annual Meeting on June 20, 2024.
• Stockholders are being asked to vote on several proposals.
• These include electing five Class A directors, ratifying the appointment of Baker Tilly US, LLP as the company's independent public accountant for the fiscal year ending December 31, 2024, and approving amendments to the company's 2017 Equity Incentive Plan to increase the number of shares issuable from 18,500,000 to 22,200,000.
• Additionally, stockholders will vote on an amendment to the company's Articles of Incorporation to increase the total number of authorized shares of common stock from 250,000,000 to 275,000,000.
• There will also be an advisory, non-binding vote on the compensation of the company's named executive officers.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating routine corporate governance activities. The proposals suggest potential growth and investment, leading to a moderately positive sentiment.

Positives

• The company is actively engaging with its shareholders through the annual meeting process.
• The proposals suggest potential growth and continued investment in the company through equity incentives.

Risks

• Failure to secure stockholder approval for the proposed amendments could limit the company's flexibility in attracting and retaining talent through equity incentives and raising capital through stock issuance.

Future Outlook

The company is seeking stockholder approval to provide greater flexibility in its equity compensation plans and authorized share capital, potentially supporting future growth initiatives.

Industry Context

Companies in the cannabis industry often use equity incentive plans to attract and retain talent due to the high-growth nature and regulatory complexities of the sector. Increasing authorized shares is a common practice to facilitate potential future capital raises or acquisitions.

Comparison to Industry Standards

• Many publicly traded cannabis companies, such as Curaleaf, Trulieve, and Green Thumb Industries, regularly seek shareholder approval for similar measures related to equity compensation and authorized share capital.
• These companies often benchmark their executive compensation against industry peers to ensure competitiveness.
• Auditor ratification is a standard practice for publicly traded companies across all sectors.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through their votes.
• Employees may be affected by changes to the equity incentive plan.
• The outcome of the proposals could impact the company's financial flexibility and future growth prospects.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting on June 20, 2024, to discuss and vote on the proposals.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Director Election, Equity Incentive Plan, Authorized Shares, Executive Compensation, Baker Tilly, Schwazze, Medicine Man Technologies